First half-year profit debut, net profit reached 450 million, BeiGene is 'killing it'

Recently, BeiGene delivered an inspiring interim report: total operating revenue reached 17.518 billion yuan, a year-on-year increase of 46%; net profit attributable to the parent company was 450 million yuan, marking the first half-year profit since its listing.

This milestone not only signifies that China's leading biotech company has achieved the critical transition from 'capital infusion' to 'self-sufficiency,' but also reflects the profound transformation of China's innovative drug industry in the global competitive landscape.

In recent years, as challenges such as medical insurance cost control intensify, the profitability of innovative pharmaceutical companies has become a core indicator to test their business models.

Moreover, BeiGene's turnaround coincides with the global sales of its core product, zanubrutinib, exceeding 12.5 billion yuan, and its consecutive two-quarter outperformance in the U.S. market against AstraZeneca's acalabrutinib and Johnson & Johnson's ibrutinib, topping the BTK inhibitor sales chart. Behind this achievement lies the strategic inspiration for Chinese innovative drug companies on how to break through 'involution' and compete in the global market.

Profit turning point in the first half of the year, global momentum unleashed

The financial report shows that in the first half of 2025, BeiGene's total operating revenue reached 17.518 billion yuan, a year-on-year increase of 46.0%. Product revenue accounted for 17.360 billion yuan, up 45.8% year-on-year.

Notably, during the reporting period, the company achieved an operating profit of 799 million yuan and a net profit attributable to the parent company of 450 million yuan, successfully turning losses into profits compared to the same period last year.

This marks BeiGene's first comprehensive profit in operating profit and net profit attributable to the parent company this year. The announcement indicates that this profitability was primarily driven by significant growth in product revenue, while cost management also contributed to operational efficiency improvements.

Based on this performance, BeiGene updated its revenue guidance, adjusting the full-year 2025 revenue forecast from the original range of 35.2 billion to 38.1 billion yuan to 35.8 billion to 38.1 billion yuan.

Additionally, the gross margin was updated to the mid-to-high range of 80% to 90%. In terms of cash flow, the net cash flow from operating activities after deducting capital expenditures such as fixed asset investments is expected to be positive for the full year.

In its global expansion, tislelizumab's global footprint continues to expand, with approvals now obtained in 47 markets. This quarter, the drug was newly included in reimbursement programs in 20 markets, including Japan, Europe, and Australia.

Since its launch in 2019, tislelizumab has covered key cancer types such as urothelial carcinoma and non-small cell lung cancer, benefiting millions of patients worldwide.

While global commercialization progresses steadily, BeiGene's pipeline R&D is also at a critical development stage, with multiple catalytic events expected in the near future. The financial report indicates that over the next 18 months, the company anticipates more than 20 milestone achievements in its hematologic and solid tumor pipelines.

Supporting this breakthrough is BeiGene's fully integrated, end-to-end R&D model. By focusing on differentiated, in-house R&D to address unmet patient needs, conducting early exploration with low incremental costs, and combining rapid proof-of-concept validation, BeiGene has accelerated the transition from lab to clinic.

According to previous R&D Day disclosures, from 2019 to 2023, BeiGene advanced 15 self-developed new molecular entities into clinical stages. In 2024 alone, over 10 new molecular entities entered clinical trials, demonstrating BeiGene's efficient R&D progress.

Meanwhile, BeiGene has established a robust global clinical development platform covering multiple stages, therapeutic modalities, and disease areas. To date, the company has conducted over 170 trials in 40 countries and regions, enrolling more than 25,000 patients.

'Single-product breakthrough' achieved, 'comprehensive ecosystem' further upgraded

In the first half of 2025, BeiGene continued to demonstrate strong execution capabilities and global growth momentum, with product revenue rising to 17.360 billion yuan, up from 11.908 billion yuan in the same period last year. This growth was primarily driven by increased sales of its self-developed products, BRUKINSA® (zanubrutinib), tislelizumab, and Amgen-authorized products.

As a BTK inhibitor, zanubrutinib's global sales exceeded market expectations again, reaching 12.527 billion yuan in the first half, a year-on-year increase of 56.2%. The U.S. market contributed significantly, with sales of 8.958 billion yuan, up 51.7% year-on-year, driven by strong demand across all indications and favorable net pricing.

With its differentiated and best-in-class clinical profile, zanubrutinib continues to lead in new patient market share among BTK inhibitors. U.S. market data shows that zanubrutinib has topped the BTK inhibitor sales chart for two consecutive quarters, with its lead expanding.

Financial report data reveals that in Q2 2025, zanubrutinib sales in the U.S. reached $684 million, up 43% year-on-year; acalabrutinib sales were $583 million, up 5%; and ibrutinib sales were $543 million, down 9%.

Beyond the U.S., zanubrutinib performed exceptionally well in Europe and China. In the first half of 2025, its European sales reached 1.918 billion yuan, up 81.4% year-on-year, with market share increasing in key markets like Germany, Italy, and Spain. In China, zanubrutinib maintained its lead in the BTK inhibitor space, with sales of 1.192 billion yuan, up 36.5% year-on-year.

BeiGene's other core product, the PD-1 inhibitor tislelizumab, reported sales of 2.643 billion yuan in the first half, up 20.6% year-on-year. This growth was driven by new patient demand following the inclusion of newly approved indications in China's medical insurance and increased hospital adoption. The financial report notes that tislelizumab continues to lead the Chinese PD-1 market in share.

In hematologic malignancies, BeiGene has built a portfolio of three fully self-owned products, including the BTK inhibitor zanubrutinib and two Phase 3 candidates—the BCL2 inhibitor sonrotoclax and the BTK CDAC BGB-16673.

Particularly in chronic lymphocytic leukemia (CLL), these three differentiated and synergistic products are poised to address unmet needs across CLL patient segments.

In solid tumors, beyond the core PD-1 inhibitor tislelizumab, BeiGene boasts a rich and broad pipeline, including potential best-in-class products and combination therapies, with rapid advancements in breast, lung, and gastrointestinal cancers.

Conclusion

BeiGene's stellar interim report for 2025 not only marks a milestone in Chinese innovative drug companies' transition from 'burning cash on R&D' to 'self-sufficiency,' but also highlights the success of its global strategy. Its consecutive quarterly outperformance against top competitors in the U.S. validates the commercial potential of 'best-in-class' drugs.

The profit turning point is driven by both revenue structure optimization and cost control, while the anticipated 20+ R&D milestones over the next 18 months inject sustained momentum into its 'pipeline ecosystem' strategy.

From 'single-product breakthrough' to 'comprehensive upgrade,' BeiGene is redefining the growth trajectory of Chinese innovative drug companies with its triple barriers of clinical value, global capabilities, and efficient R&D.